448 related articles for article (PubMed ID: 29857892)
1. Tumor mutation burden to tumor burden ratio and prediction of clinical benefit of anti-PD-1/PD-L1 immunotherapy.
Qin BD; Jiao XD; Zang YS
Med Hypotheses; 2018 Jul; 116():111-113. PubMed ID: 29857892
[TBL] [Abstract][Full Text] [Related]
2. Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review.
Teng F; Meng X; Kong L; Yu J
Cancer Lett; 2018 Feb; 414():166-173. PubMed ID: 29155348
[TBL] [Abstract][Full Text] [Related]
3. Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy.
Ren D; Hua Y; Yu B; Ye X; He Z; Li C; Wang J; Mo Y; Wei X; Chen Y; Zhou Y; Liao Q; Wang H; Xiang B; Zhou M; Li X; Li G; Li Y; Zeng Z; Xiong W
Mol Cancer; 2020 Jan; 19(1):19. PubMed ID: 32000802
[TBL] [Abstract][Full Text] [Related]
4. Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy.
Goodman AM; Sokol ES; Frampton GM; Lippman SM; Kurzrock R
Cancer Immunol Res; 2019 Oct; 7(10):1570-1573. PubMed ID: 31405947
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers.
Yarchoan M; Albacker LA; Hopkins AC; Montesion M; Murugesan K; Vithayathil TT; Zaidi N; Azad NS; Laheru DA; Frampton GM; Jaffee EM
JCI Insight; 2019 Mar; 4(6):. PubMed ID: 30895946
[TBL] [Abstract][Full Text] [Related]
6. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
Meng X; Huang Z; Teng F; Xing L; Yu J
Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
[TBL] [Abstract][Full Text] [Related]
7. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
[TBL] [Abstract][Full Text] [Related]
8. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.
Goodman AM; Kato S; Bazhenova L; Patel SP; Frampton GM; Miller V; Stephens PJ; Daniels GA; Kurzrock R
Mol Cancer Ther; 2017 Nov; 16(11):2598-2608. PubMed ID: 28835386
[TBL] [Abstract][Full Text] [Related]
9. Predictive Biomarkers for Immunotherapy Response Beyond PD-1/PD-L1.
Darabi S; Braxton DR; Eisenberg BL; Demeure MJ
Oncology (Williston Park); 2020 Aug; 34(8):321-327. PubMed ID: 32785929
[TBL] [Abstract][Full Text] [Related]
10. Tumor Mutational Burden and
Barroso-Sousa R; Keenan TE; Pernas S; Exman P; Jain E; Garrido-Castro AC; Hughes M; Bychkovsky B; Umeton R; Files JL; Lindeman NI; MacConaill LE; Hodi FS; Krop IE; Dillon D; Winer EP; Wagle N; Lin NU; Mittendorf EA; Van Allen EM; Tolaney SM
Clin Cancer Res; 2020 Jun; 26(11):2565-2572. PubMed ID: 32019858
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
[TBL] [Abstract][Full Text] [Related]
12. Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy.
Fang XN; Fu LW
Recent Pat Anticancer Drug Discov; 2016; 11(2):141-51. PubMed ID: 26916881
[TBL] [Abstract][Full Text] [Related]
13. Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients.
Nikanjam M; Arguello D; Gatalica Z; Swensen J; Barkauskas DA; Kurzrock R
Int J Cancer; 2020 Jun; 146(11):3087-3097. PubMed ID: 31479512
[TBL] [Abstract][Full Text] [Related]
14. Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer.
Chae YK; Davis AA; Raparia K; Agte S; Pan A; Mohindra N; Villaflor V; Giles F
Clin Lung Cancer; 2019 Mar; 20(2):88-96.e6. PubMed ID: 30425022
[TBL] [Abstract][Full Text] [Related]
15. The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.
van Dam LS; de Zwart VM; Meyer-Wentrup FA
Pediatr Blood Cancer; 2015 Feb; 62(2):190-197. PubMed ID: 25327979
[TBL] [Abstract][Full Text] [Related]
16. The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy.
Knepper TC; Montesion M; Russell JS; Sokol ES; Frampton GM; Miller VA; Albacker LA; McLeod HL; Eroglu Z; Khushalani NI; Sondak VK; Messina JL; Schell MJ; DeCaprio JA; Tsai KY; Brohl AS
Clin Cancer Res; 2019 Oct; 25(19):5961-5971. PubMed ID: 31399473
[TBL] [Abstract][Full Text] [Related]
17. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
18. Frameshift events predict anti-PD-1/L1 response in head and neck cancer.
Hanna GJ; Lizotte P; Cavanaugh M; Kuo FC; Shivdasani P; Frieden A; Chau NG; Schoenfeld JD; Lorch JH; Uppaluri R; MacConaill LE; Haddad RI
JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467336
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers of response to PD-1/PD-L1 inhibition.
Maleki Vareki S; Garrigós C; Duran I
Crit Rev Oncol Hematol; 2017 Aug; 116():116-124. PubMed ID: 28693793
[TBL] [Abstract][Full Text] [Related]
20. Programmed death 1 (PD-1) and its ligand (PD-L1) as a new frontier in cancer Immunotherapy and challenges for the Pathologist: state of the art.
Callea M; Pedica F; Doglioni C
Pathologica; 2016 Jun; 108(2):48-58. PubMed ID: 28195250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]